
Klaus Gerwert and Grischa Gerwert in a betaSENSE laboratory
Photo Credit: © Dennis Yenmez/Stadt Bochum
Scientific Frontline: Extended "At a Glance" Summary: Immuno-Infrared Sensor for Neurodegenerative Disease Detection
The Core Concept: A novel blood test utilizing an immuno-infrared sensor platform to detect the earliest biological signs of Alzheimer’s and Parkinson’s diseases prior to the onset of clinical symptoms.
Key Distinction/Mechanism: Unlike conventional symptom-oriented diagnostics, this technology uses specific antibodies immobilized on a sensor to isolate misfolded protein biomarkers—amyloid beta (Aβ) for Alzheimer’s and alpha-synuclein (α-Syn) for Parkinson’s—directly from complex body fluids. The degree of protein misfolding is then accurately quantified using highly sensitive quantum cascade laser technology combined with infrared spectroscopy.
Major Frameworks/Components:
- Biomarker Isolation: The strategic use of specific antibodies to capture targeted neurodegenerative proteins directly from blood samples.
- Quantum Cascade Laser Technology: Advanced infrared spectroscopy that sensitively detects secondary-structure-specific changes and misfolding in target proteins.
- Patented Surface Chemistry: A specialized sensor coating that successfully immobilizes antibodies, paired with a blocking layer that prevents non-specific binding from background fluids.
- Difference Spectroscopy: A computational and optical method to extract the targeted biomarker's precise spectrum from the complex background noise of the body fluid.


.jpg)








.png)

